Specifically, our gene-based score using HDL-raising variation at the CETP locus predicted that CETP-based inhibition would elevate BC risk (OR = 1.11, 95% CI = 1.04–1.18, P < 0.001). The gene discussed is CETP; the disease is breast cancer.